1. Home
  2. DRCT vs VTVT Comparison

DRCT vs VTVT Comparison

Compare DRCT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Direct Digital Holdings Inc.

DRCT

Direct Digital Holdings Inc.

HOLD

Current Price

$3.61

Market Cap

532.4K

Sector

Technology

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$36.89

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRCT
VTVT
Founded
2018
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
532.4K
148.7M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
DRCT
VTVT
Price
$3.61
$36.89
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$32.00
$53.00
AVG Volume (30 Days)
272.7K
45.7K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,694,000.00
N/A
Revenue This Year
$5.42
N/A
Revenue Next Year
$9.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$14.00
52 Week High
$7.21
$44.00

Technical Indicators

Market Signals
Indicator
DRCT
VTVT
Relative Strength Index (RSI) 54.84 56.38
Support Level $0.38 $34.29
Resistance Level $6.04 $41.59
Average True Range (ATR) 0.83 2.23
MACD -0.14 0.74
Stochastic Oscillator 12.14 82.09

Price Performance

Historical Comparison
DRCT
VTVT

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: